ClinicalTrials.gg
RecruitingNCT06642961Updated Oct 15, 2024

A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase II Trail Evaluating the Efficacy and Safety of GR1802 Injection in Patients with Moderate to Severe Asthma

A Phase 2 interventional study of GR1802 injection and GR1802 injection in Asthma, sponsored by Genrix (Shanghai) Biopharmaceutical Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-10-15.

Sponsored by Genrix (Shanghai) Biopharmaceutical Co., Ltd. (part of Chongqing Genrix Biopharmaceutical Co., Ltd) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Mar 2025, 1 year 7 months ago, but the record still lists the study as recruiting.
  • Registered 2 years 2 months after the study started (first participant enrolled Jul 2022, registered Oct 2024).
  • Started Jul 2022; still recruiting 4 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 251 studies in Asthma with a site in China — 87 open to participants now, 96 under way, 15 of them phase 3. Asthma · China.

Planned enrollment
110th of 182
150 · median 203
Started
2022
with 20 others
Phase 2
39 of 251
19 open now
Primary completion
2025-03
later than 11 of 95 live
Registered
181st of 251
by date

Among the 251 studies in Asthma with a site in China, this one is the 110th largest by planned enrollment of the 182 interventional ones that give a count, is one of 21 that started in 2022, is one of 39 in phase 2, reaches primary completion later than 11 of the 95 other live ones, and was the 181st registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 603 are open to participants now.

Browse Asthma studies →

Open to participants now

87 of the 251 studies in Asthma with a site in China are open now. Recruiting first, the newest first:

82 more — sign in →

All 87 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 251 studies in Asthma with a site in China, or all of them as a file.
02

Study summary

This is a multi-center, randomized, double blind, placebo-controlled study to evaluate the efficacy and safety of GR1802 injection in comparison to placebo in patients with atopic dermatitis. Patients will receive GR1802 injection or Placebo every 2 Weeks.

03

Conditions studied

  • Asthma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥18 and ≤70 years old, male or female.
  2. The subject meet the diagnostic criteria of GINA 2021 requiring a diagnosis of asthma for at least 12 months and fulfilled one of the following criteria:

(1) The subject has received medium-to-high dose ICS combined with at least one control drug, such as LABA, LTRA, theophylline, for at least 3 months before baseline visit, and maintained stable treatment regimen and dosage for at least 1 month before baseline visit; (2) The subject have been on a 3rd controlled drug for at least 3 consecutive months and on a stable dose for ≥1 month prior to baseline visit; (3) The subject must have been on maintenance therapy with ≤10mg/day prednisone or equivalent dose of OCS continuously for at least 3 months and have been receiving therapy at a stable dose for ≥1 month prior to the baseline visit.

  1. 35%≤ Pre-bronchodilator measured ≤ 80% of the normal predicted value at screening and baseline visits.
  1. Asthma Control Questionnaire-5 (ACQ-5) score ≥1.5 at screening and baseline visits.
  1. A positive bronchodilation test (≥12% increase in the FEV1 post-bronchodilator and an absolute FEV1 increase of ≥200 mL) within 12 months before screening.
  1. Subjects must have experienced at least one severe asthma exacerbation event within 12 months before screening, denfined as: systemic use of for ≥3 days (at least twice the dose of current use); and/or an emergency visit due to asthma symptoms resulting in hospitalisation, and/or asthma requiring additional systemic glucocorticoid intervention therapy.
  1. Willingness to follow the requirements of the study protocol and willingness of the patient or his/her legal representative to sign a written .

Exclusion criteria

Exclusion Criteria:

  1. (COPD) or other lung disease that may impair lung function, as judged by the investigator.
  2. Have experienced a severe asthma exacerbation event within 1 month before baseline visit.
  3. Lung disease other than asthma with impact on efficacy or safety evaluation confirmed by clinical or imaging evidence (e.g., chest X-ray, CT, MRI)within 12 months before baseline visit.
  4. Evidence of active tuberculosis infection at screening.
  5. Current smokers or former smokers who quit smoking less than 6 months.
  6. Former smokers with a smoking history of more than 10 pack-years.
  7. Subjects who have history of drug or alcohol abuse (alcohol abuse defined as consumption of more than 28 units of alcohol per week :1 unit = 285 ml of beer or 25 ml of spirits ≥40% alcohol by volume or 1 glass of wine) within 2 years before baseline visit.
  8. Long-term reversal of daily sleep patterns (e.g., long-term night shift workers).
  9. Subjects who need to be treated with non-selective β1-adrenergic receptor blockers for any reason, or who are on selective β1-blockers but have unstable doses in the 1 month prior to the baseline visit.
  10. Underwent an IgE antibody within 130 days prior to the baseline visit, or received prior treatment with an IL-4R antibody (e.g., dupilumab); and those who have received other biologics within 5 half-lives (half-life known) or 6 months (half-life unknown).
  11. Treatment with herbs and pCms with asthma-alleviating effects within 4 weeks prior to the baseline visit (except topical herbs).
  12. Underwent immunoglobulin (IVIG) therapy, allergen-specific immunotherapy (SIT) within 3 months prior to the baseline visit or plan to be treated with the therapy during the trial.
  13. Underwent bronchial thermoplasty within 3years before baseline visit or plan to be treated with the therapy during the trial.
  14. Comorbidities requiring ICS (e.g. TB) or LABA (e.g. severe heart disease, insulin-dependent diabetes mellitus, uncontrolled hypertension, hyperthyroidism, etc.) resulting in compromised treatment of the comorbidities.
  15. Prolonged or ventricular tachycardia requiring pharmacological treatment.
  16. Pregnant or lactating women.
  17. Positive surface antigen (except for HBVDNA test below 500 IU/ml) and hepatitis B core antibody (except for HBVDNA test below 500 IU/ml) at screening; positive antibody, antibody, and TP-Ab (except for those who are RPR or TRUST negative).
  18. Those with existing or suspected acute or chronic infections in the 4 weeks prior to the baseline visit and who have received antibacterial, antiviral, antifungal, antiparasitic or antiprotozoal therapy.
  19. Received live or attenuated vaccine within 12 weeks before baseline visit or planned to receive live or attenuated vaccine during the study period.
  20. History of vital organ transplantation (e.g. heart, lung, kidney, liver) or haematopoietic stem cell/bone marrow transplantation.
  21. Patients with active diseases, or autoimmune diseases being treated with drugs (e.g. inflammatory bowel disease, primary biliary cirrhosis, systemic lupus erythematosus, multiple sclerosis, psoriasis, Hashimoto's thyroiditis, Graves' disease).
  22. History of severe herpes virus infections, e.g., herpes encephalitis, disseminated herpes.
  23. within 5 yearsbefore baseline visit (except squamous carcinoma in situ, basal cell carcinoma and cervical carcinoma in situ of the skin, which have been completely treated without any sign of recurrence).
  24. Poorly controlled hypertension (systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥100 mmHg. Note: Determined by 2 consecutive elevated readings. If the initial blood pressure reading exceeds this limit, the blood pressure may be re-measured after the subject has rested for ≥10 minutes. If the repeated measurement is below the limit, the second value is acceptable).
  25. The following laboratory test abnormalities were present at screening:

    \<10.0 g/dL (100.0 g/L) (men) or \<9.0 g/dL (90.0 g/L) (women); white blood cell count \<3.0×109/L; \<1.5 x 109 /L; count \<100 x 109 /L; (ALT) and/or aspartate aminotransferase (AST) ) > 1.5 times (ULN); serum creatinine > 1.0 times ULN; total > 1.5 times ULN; alkaline phosphatase > 1.5 times ULN.

  26. Females and/or males of and their partners who refuse to: use highly effective (female subjects and their partners)/effective (male subjects and their partners) , have a childbearing, egg donation programme (females), or a sperm donation programme (males), from the time of signing the Form until 6 months after the end of the last dose;
  27. Participation in another clinical trial treatment within 12 weeks prior to the baseline visit.
  28. The investigator considers that there are any conditionswhich are inappropriate to participate in this study.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    GR1802 300mg Q2W

    GR1802 is injected subcutaneously (SC) with a loading dose of 600 mg at the first dose, and then 300 mg each time, once every 2 weeks (Q2W) for a total of 12 doses.

    Drug: GR1802 injection

  • Experimental
    GR1802 150mg Q2W

    GR1802 is injected subcutaneously (SC) with a loading dose of 300 mg at the first dose, and then 150 mg each time, once every 2 weeks (Q2W) for a total of 12 doses.

    Drug: GR1802 injection

  • Placebo comparator
    Placebo

    Subcutaneous injection (SC), once every 2 weeks (Q2W) for a total of 12 doses

    Other: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change from baseline in pre-bronchodilator FEV1 (forced expiratory volume in 1 second) at 12 weeks.

    Absolute change from baseline in pre-bronchodilator FEV1 in each dose group at 12 weeks of GR1802 treatment compared with placebo.

    Time frame: 12weeks

Secondary outcomes

  1. Change from baseline in pre-bronchodilator FEV1 at 24 weeks.

    Absolute change from baseline in pre-bronchodilator FEV1 at e24 weeks.

    Time frame: 24weeks

  2. Percent change from baseline in pre-bronchodilator FEV1 at 12 and 24 weeks.

    Percent change from baseline in pre-bronchodilator FEV1 at 12 and 24 weeks.

    Time frame: 12weeks and 24weeks

  3. Annualized rate of subjects experiencing severe asthma exacerbations.

    Annualized rate of subjects experiencing severe asthma exacerbations during the 24-week randomized treatment and throughout the trial period.

    Time frame: 24weeks and 32weeks

  4. Time to the first onset of the severe asthma exacerbation event.

    Time from baseline to the first onset of the severe asthma exacerbation event.

    Time frame: 32weeks

  5. Annualized rate of subjects experiencing the event of loss of asthma control (LOAC).

    Annualized rate of subjects experiencing the event of loss of asthma control (LOAC) during the 24-week randomized treatment and throughout the trial period.

    Time frame: 24weeks and 32weeks

  6. Time to the onset of the first event of LOAC.

    Time from baseline to the onset of the first event of LOAC.

    Time frame: 32weeks

  7. Change from baseline in other lung function measures.

    Changes from baseline in FEV1 percentage of predicted value (FEV1% Pred) and Peak diurnal and nocturnal expiratory flow (PEF)

    Time frame: 24weeks

  8. Changes from baseline in the Asthma Control Questionnaire-5 (ACQ-5)score and ACQ-7 score at each evaluation time point.

    The ACQ-5 is a questionnaire used to evaluate the degree of asthma control. Each question is scored from 0 to 6 (on a 7-point scale) according to its severity. The higher the score, the less satisfactory symptom control is.

    Time frame: 2、4、8、12、16、20、24、28 、32weeks

  9. Change from baseline in the Asthma Quality of Life Questionnaire (AQLQ) score at 12weeks and 24 weeks.

    The AQLQ is a disease-specific health-related quality of life instrument that taps both physical and emotional impact of disease. Scores range 1-7, with higher scores indicating better quality of life.

    Time frame: 12weeks and 24weeks

  10. Total daily use of asthma reliever

    Total daily use of asthma relief medication

    Time frame: 24weeks

  11. Safety evaluation indicators

    Safety evaluation indicators: Adverse Events, Laboratory Tests, Vital Signs, Electrocardiograms, Physical Examination, etc.

    Time frame: 32weeks

  12. Concentration of GR1802 at each evaluation time point.

    To evaluate the trough concentration at steady-state of GR1802 for each dose group. Population pharmacokinetic analysis is performed using a nonlinear mixed-effects model.

    Time frame: Baseline up to week 32

  13. Anti-drug antibodies (ADAs) and neutralizing antibodies (Nabs).

    Incidence of anti-drug antibodies (ADAs) and neutralizing antibodies (Nabs) (if applicable).

    Time frame: Baseline up to week 32

07

Study locations

1 of 1 sites recruiting
  • The First Affiliated Hospital of Guangzhou Medical University
    Guangzhou, Guangdong 510120, China
    Recruiting
    • Nanshan Zhong, PhD. · Contactchen_rch@163.com · 020-34296151
    • Ruchong Chen, PhD. · Contact02034296151
    • Nanshan Zhong, PhD. · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2022 (actual). Primary completion is estimated for Mar 2025, 32 months after the start.

Of 137 industry-sponsored phase 2 interventional studies under Asthma, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 23. This study's planned 32 months is above that.

Counting every sponsor, half of 199 studies reached it within 20 months; a quarter within 12 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 14, 2024
First posted
Oct 15, 2024
StartActual
Jul 19, 2022
Primary completionEst.
Mar 31, 2025
CompletionEst.
Dec 31, 2025
Last update
Oct 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06642961
Responsible party
Sponsor
First posted
Oct 15, 2024
Start date
Jul 19, 2022
Primary completion
Mar 31, 2025 (estimated)
Completion
Dec 31, 2025 (estimated)
Last update
Oct 15, 2024

Study contacts

Nanshan Zhong, PhD.
Contact
chen_rch@163.com
020-34296151
Ruchong Chen, PhD.
Contact
chen_rch@163.com
13710723826

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Telikibart

Start the discussion